Oxaliplatin Amarox

Oxaliplatin, the active ingredient in Oxaliplatin Amarox, is a platinum‑based chemotherapy presented as a injection for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve the gastrointestinal tract.

- Colorectal cancer: Improves survival by inhibiting tumor cell proliferation. - Gastric cancer: Used in combination regimens to enhance tumor response. - Pancreatic cancer: Contributes to disease control when added to multi‑drug protocols. - Ovarian cancer: Provides additional cytotoxic effect in refractory cases. - Esophageal cancer: Used as part of neoadjuvant chemoradiation schedules. - Metastatic disease: Helps reduce tumor burden in various metastatic solid tumours.

Oxaliplatin may elicit a range of adverse reactions, from mild to severe, depending on individual tolerance and treatment context.

Common Side Effects: - Nausea and vomiting: Frequent mild to moderate episodes. - Peripheral neuropathy: Tingling or numbness, often dose‑dependent. - Diarrhea: Loose stools that may require supportive care. - Fatigue: Generalized tiredness affecting daily activities. - Thrombocytopenia: Reduced platelet count, increasing bleeding risk. - Elevated liver enzymes: Mild transaminase rise detectable in labs.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: Anaphylaxis or bronchospasm. - Acute neurotoxicity: Sudden onset of muscle weakness or respiratory difficulty. - Persistent peripheral neuropathy: Long‑lasting sensory deficits. - Hemolytic anemia: Destruction of red blood cells. - Renal impairment: Decline in kidney function requiring monitoring.

When using Oxaliplatin, clinicians should assess patient history and monitor for specific safety concerns.

- Renal function: Evaluate baseline creatinine and adjust if impaired. - Neuropathy risk: Monitor for sensory changes and modify dosing if needed. - Hematologic status: Check complete blood counts before each cycle. - Pregnancy and lactation: Contraindicated; avoid use in pregnant or nursing women. - Drug hypersensitivity: Review prior reactions to platinum agents. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Oxaliplatin may interact with other medicines, altering efficacy or safety. Clinicians should review concomitant therapies.

Major Interactions (Avoid): - Aminoglycoside antibiotics: Increased risk of nephrotoxicity. - High‑dose vitamin C: May reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants: Enhanced bleeding tendency.\n- Antiemetic agents: Potential for additive sedation. - CYP450 inducers: May affect drug clearance indirectly. - NSAIDs: Possible impact on platelet function. - Radiotherapy: Combined neurotoxicity risk.